Avacta Announces Distribution Agreement With ABCAM plc
06 April 2021 - 8:21PM
Business Wire
Global distribution agreement with ABCAM plc to
sell Avacta’s SARS-CoV-2 research ELISA Affimer reagents
Avacta Group plc (AIM: AVCT), the developer of innovative cancer
therapies and diagnostics based on its proprietary Affimer® and
pre|CISION™ platforms, is pleased to announce that it has entered
into a global distribution agreement with ABCAM plc (AIM: ABC;
NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2
research ELISA Affimer® reagents.
Avacta has developed Affimer® reagents which can be used in a
high performance ELISA laboratory test to detect the SARS-CoV-2
spike protein with high sensitivity and excellent specificity for
the spike protein of the original strain of the virus and other
dominant variants such as B117 (“Kent” strain) and D614G.
ABCAM is one of the world’s leading suppliers of high-quality
biological reagents and kits which are used in a wide range of
fields including drug discovery, diagnostics and basic research.
Under the worldwide, non-exclusive distribution agreement, ABCAM
will enable the global research community to access Avacta’s
SARS-CoV-2 spike protein Affimer® research reagents through its
on-line catalogue. This will allow scientists around the world to
perform the ELISA test in their own laboratories and support the
global fight against the pandemic.
Dr Alastair Smith, Chief Executive of Avacta Group
commented: “We are delighted that we have established a global
route to market for the SARS-CoV-2 spike protein Affimer® reagents
through ABCAM’s dedicated global commercialisation
infrastructure.
As far as we are aware, our spike protein ELISA test is the most
sensitive test of its kind and, in ABCAM, we have a world-leading
partner capable of maximising the commercial potential of the
Affimer® reagents by making them globally available to scientists
who are researching into the SARS-CoV-2 coronavirus.
I look forward to further updating the market on progress across
the Group in due course.”
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
Article 7 of Regulation (EU) No 596/2014 (MAR).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005525/en/
Zyme Communications (Trade and Regional Media) Katie
Odgaard Tel: +44 (0) 7787 502 947
katie.odgaard@zymecommunications.com
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024